|
|
|
|
|
Gemifloxacin: profile and news
Oscient Pharmaceuticals Reports Financial Results for Fourth ... 07 Mar 2006 Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities ... Mar 2, 2006 Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ... Feb 22, 2006 Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ... Feb 7, 2006 Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ... Feb 7, 2006 Oscient Pharmaceuticals y Pfizer celebran acuerdo por las... Feb 7, 2006 Pfizer acquires rights to Oscient antibiotic in Mexico Feb 9, 2006 Robust Viral Load Reduction Successfully Achieved in Phase II ... Feb 14, 2006 Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO & ... 09 Feb 2006 Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ... Jan 9, 2006 New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the ... Dec 9, 2005 Oscient Pharmaceuticals to Present at First Albany Capital Annual ... Nov 29, 2005 Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ... Oct 7, 2005 Clinical Data on FACTIVE(R) Tablets to be Presented at the 43rd ... Sep 30, 2005 Clinical Data on FACTIVE Tablets to be Presented at the 43rd ... Sep 30, 2005 Full Results Released From Phase III Trial Comparing Five-Day and ... Sep 18, 2005 Full Results Released from Phase III Trial Comparing Five-Day and ... Sep 18, 2005 Oscient Pharmaceuticals Completes Sales Force Expansion; Company ... Oct 3, 2005 Legionnaires' disease - Legionellosis Oct 6, 2005 Oscient Pharmaceuticals Files Shelf Registration Statement Sep 30, 2005 Many meds don't mix with the sun Sep 21, 2005 Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare ... Sep 2, 2005 Oscient Pharmaceuticals Reports Financial Results for Second ... Aug 2, 2005 Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ... Jul 19, 2005 Oscient Pharmaceuticals Achieves Primary Endpoint in Phase III ... Jun 6, 2005 Other information Indication For the treatment of Bacterial infection caused by susceptible strains such as S.pneumoniae, H.influenzae, H.parainfluenzae, or M.catarrhalis, S.pneumoniae (including multi-drug resistant strains [MDRSP]), M.pneumoniae, C.pneumoniae, or K.pneumoniae. Pharmacology Gemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Mechanism Of Action The bactericidal action of Gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Drug Category Anti-bacterial Agents; ATC:J01MA15 Brand Names/Synonyms Factive; Gemifloxacin; Gemifloxacin Mesilate; Gemifloxacin [Inn] Dosage Forms TABLET Absorption Gemifloxacin is rapidly absorbed from the gastrointestinal tract. The absolute bioavailability of the 320 mg tablet averaged approximately 71% (95% CI 60%-84%). Interactions -->Interactions for Gemifloxacin: Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects. Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance. Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin. FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy. However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives. Quinolones form chelates with alkaline earth and transition metals. The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium. Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE. Sucralfate should not be taken within 2 hours of FACTIVE. Chemical IUPAC Name 1-acetyloxycyclohexane-1-carboxylicacid Chemical Formula C18H20FN5O4 Half Life 7 (+/- 2) hours Drug Type Approved Drug # Accession No APRD00053 CAS Registry Number 175463-14-6 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |